Chondrosarcomas are the most common malignant tumors of the cartilage, are seen predominantly in adults, and have varied clinical behavior. The majority of them affect the medullary canal of long bones and pelvic bones. The prognosis of chondrosarcoma is closely related to histological grading; however, the grading is subject to interobserver variability. Conventional chondrosarcomas are overall considered to be chemotherapy-and radiation-resistant, resulting in limited treatment options. The majority of advanced conventional chondrosarcomas are treated with chemotherapy without any survival benefit. Recent studies have evaluated molecular genetic findings which have improved the understanding of chondrosarcoma biology. Newer therapeutic targets are desperately needed. In this review article, we explore ongoing clinical trials evaluating novel ways of treating advanced conventional chondrosarcoma.

Original languageEnglish
Article number1962
Pages (from-to)1-12
Number of pages12
Issue number7
StatePublished - Jul 2020


  • Chemotherapy
  • Chondrosarcoma
  • Cyclin-dependent kinase inhibitors
  • Immunotherapy
  • Isocitrate dehydrogenase
  • Targeted therapy


Dive into the research topics of 'Non-conventional treatments for conventional chondrosarcoma'. Together they form a unique fingerprint.

Cite this